A Multicenter, Open-label, Randomized, 2-arm, Phase II Trial of Pharmacodynamics, Pharmacokinetics and Safety of Two Dose Regimens of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon.

Trial Profile

A Multicenter, Open-label, Randomized, 2-arm, Phase II Trial of Pharmacodynamics, Pharmacokinetics and Safety of Two Dose Regimens of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Alisporivir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Acronyms ALtitude II
  • Sponsors Debiopharm; Novartis
  • Most Recent Events

    • 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Apr 2015 Planned End Date changed from 1 Oct 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
    • 25 Apr 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top